Kiniksa Pharmaceuticals delivered a robust third quarter in 2025, with total revenue reaching $180.9 million, primarily fueled by ARCALYST net product revenue which grew 61% year-over-year. The company achieved a net income of $18.4 million, a significant improvement from a net loss in the prior year, and increased its cash, cash equivalents, and short-term investments to $352.1 million.
ARCALYST net product revenue for Q3 2025 was $180.9 million, marking a 61% year-over-year increase.
The company reported a net income of $18.4 million for the third quarter of 2025, a turnaround from a net loss of $12.7 million in Q3 2024.
Cash, cash equivalents, and short-term investments increased by $44.3 million in Q3 2025, reaching $352.1 million.
Kiniksa raised its 2025 ARCALYST net product revenue guidance to between $670 million and $675 million.
Kiniksa Pharmaceuticals has raised its full-year 2025 ARCALYST net product revenue guidance and expects to remain cash flow positive on an annual basis, with key clinical trial data for KPL-387 anticipated in the second half of 2026.
Analyze how earnings announcements historically affect stock price performance